Form 4: Neogenomics Director Lynn A. Tetrault Acquires 7,000 Shares of Common Stock

Director Lynn A. Tetrault reports acquisition of 7,000 shares of Neogenomics Inc. common stock at $8.1392 per share.

Summary

• On May 9, 2025, Lynn A. Tetrault, a director of Neogenomics Inc., acquired 7,000 shares of common stock at a price of $8.1392 per share.
• Following the transaction, Ms. Tetrault directly owns 61,398 shares of common stock and indirectly owns 7,000 shares through a Lynn Tetrault Rollover IRA.
• Ms. Tetrault also holds various stock options to purchase common stock at exercise prices ranging from $8.10 to $41.76, with expiration dates between 2026 and 2034.
• Additionally, Ms. Tetrault holds 12,254 Restricted Stock Units that vest on June 1, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports a transaction. The director's purchase is a mildly positive signal, but not strong enough to significantly shift sentiment.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The director's stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Neogenomics, NEO, Lynn Tetrault, Director, Stock Acquisition, Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units